No Data
No Data
Institutions Along With Private Equity Firms Who Hold Considerable Shares InChongqing Genrix Biopharmaceutical Co., Ltd. (SHSE:688443) Come Under Pressure; Lose 5.6% of Holdings Value
Key Insights Significant control over Chongqing Genrix Biopharmaceutical by private equity firms implies that the general public has more power to influence management and governance-related decisions
Zhixiang Jintai (688443.SH): the preventive tetanus drug "GR2001 injection" has been included in the list of breakthrough therapies.
Zhixiang Jintai (688443.SH) announced that the company's pharmaceutical, GR2001 injection, has been approved by the National Medical Products Administration of China.
Zhixiang Jintai (688443.SH): At the end of the term, Jiang Ren, the actual controller, increased the company's shares by about 31.22,200 yuan
Gelonghui, May 17, 丨 Zhixiang Jintai (688443.SH) announced that as of May 16, 2024, the actual controller, Mr. Jiang Rensheng, had increased his holdings of the company's 875,582 shares through centralized bidding through the Shanghai Stock Exchange trading system, accounting for about 0.24% of the company's total issued share capital. The total increase amount amount of about RMB 31.22,200 million has been reached, reaching the lower limit of the increase range of RMB 30 million. The period of this increase plan has expired and the implementation of the increase in holdings has been completed.
Is Chongqing Genrix Biopharmaceutical (SHSE:688443) Using Too Much Debt?
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says 'The biggest investment risk is not the volatility of prices, but whether you will
Zhixiang Jintai (688443.SH) reported first-quarter results with a net loss of 164 million yuan
Zhixiang Jintai (688443.SH) released its report for the first quarter of 2024, with revenue of 6,330.27...
Guoxin Securities: The pharmaceutical industry is entering an upward inflection point in the medium to long term, and focus on high growth targets in the quarterly report in the short term
The pharmaceutical industry currently has low growth, low profitability, undervaluation, and low transaction attention, and is entering a major layout range at an upward inflection point in the medium to long term.
No Data